Cardiology

Cangrelor superior to clopidogrel in CHAMPION PHOENIX trial

The experimental anti-clotting drug cangrelor solidly outperformed commonly used clopidogrel in a large global trial of patients who underwent coronary stent procedures, according to data from the phase III CHAMPION PHOENIX ...

Cardiology

New biolimus stent equal to everolimus stent at one year

In a match-up of Japan's top drug-releasing stent and a new device featuring a biodegradable coating, the newcomer delivered statistically comparable one-year results, according to data from the NEXT trial presented today ...

Cardiology

A five-point plan to reduce heart attack deaths in Australia

Out of the 10,021 Australian who died of a heart attack in 2010, 5305 were experiencing their second such event. Systematic national reforms are needed to reduce the alarming number of people having a second heart attack ...

Diabetes

In STEMI, diabetes linked to worse long-term outcomes

(HealthDay)—In patients undergoing primary angioplasty for ST-segment elevation myocardial infarction (STEMI), diabetes is associated with worse long-term outcomes, including mortality, reinfarction, stent thrombosis, and ...

page 22 from 34